Skip to content
MARKETS / NASDAQ / INBS
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Intelligent BIO Solutions Inc. INBS

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.2M
▲ 38.1% YoY
$-12.4M
$-12.1M
In brief

What this company does

Intelligent Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. Our headquarters are in New York City. Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited (“IFP”), a company registered in England and Wales.

Written from the business description in Intelligent Bio Solutions Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 19 August 2026. Every sentence was checked against that document before publication.

Growth
USD 4.2M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.2 · Net income -12.4
2M4M-5M-10M2019202020212022202320242025
Compound annual growth
+49.7%
+16.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +16.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−296 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -299.1% · Net -295.8%
-500%-1000%-1500%2019202020212022202320242025
ROE
FY2025 · ROE -292.3%
-100%-200%2019202020212022202320242025

Each USD of equity lost 292 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -12.1
-5M-10M2019202020212022202320242025

Total assetsUSD 11.9M
EquityUSD 5.5M
CashUSD 4.0M
Gross debtUSD 0.00
Net debtUSD -4.0M
Current ratio1.44×

The company holds more cash than debt.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0··
Income tax $B·······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0····
EPS, diluted $−8.44−20.04−6.38−127.00−11.33−0.68−0.37
Dividend / sh $·······
Payout %·······
ROE %−292.3−186.6−167.5−204.0−76.6−142.6·
Shares out B0.000.000.000.000.010.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 63 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2019

Share this section

Download image